NASDAQ:SLP - Simulations Plus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $84.25
  • Forecasted Upside: 27.38 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$66.14
▼ -4.4 (-6.24%)
1 month | 3 months | 12 months
Get New Simulations Plus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$84.25
▲ +27.38% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Simulations Plus in the last 3 months. The average price target is $84.25, with a high forecast of $95.00 and a low forecast of $76.00. The average price target represents a 27.38% upside from the last price of $66.14.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Simulations Plus. This rating has held steady since September 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2021OppenheimerBoost Price Target$79.00 ➝ $85.00High
i
1/12/2021Craig HallumDowngradeBuy ➝ HoldHigh
i
11/25/2020Taglich BrothersUpgradeSpeculative Buy ➝ Buy$76.00High
i
Rating by H. Halpern at Taglich Brothers
11/17/2020Craig HallumBoost Price TargetBuy$75.00 ➝ $81.00High
i
10/16/2020Raymond JamesInitiated CoverageOutperform$95.00Low
i
9/8/2020OppenheimerInitiated CoverageOutperform$79.00High
i
7/10/2020Craig HallumBoost Price TargetBuy$56.00 ➝ $75.00High
i
6/8/2020Craig HallumBoost Price TargetBuy$40.00 ➝ $56.00Low
i
1/6/2020Craig HallumInitiated CoverageBuy$40.00High
i
1/16/2019Taglich BrothersDowngradeBuy ➝ Speculative BuyMedium
i
Rating by H. Halpern at Taglich Brothers
(Data available from 3/4/2016 forward)
Simulations Plus logo
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
Read More

Today's Range

Now: $66.14
$65.80
$70.93

50 Day Range

MA: $77.66
$70.54
$89.52

52 Week Range

Now: $66.14
$26.00
$90.92

Volume

188,404 shs

Average Volume

216,056 shs

Market Capitalization

$1.32 billion

P/E Ratio

129.69

Dividend Yield

0.34%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Simulations Plus?

The following equities research analysts have issued stock ratings on Simulations Plus in the last twelve months: Craig Hallum, Oppenheimer Holdings Inc., Raymond James, Taglich Brothers, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for SLP.

What is the current price target for Simulations Plus?

4 Wall Street analysts have set twelve-month price targets for Simulations Plus in the last year. Their average twelve-month price target is $84.25, suggesting a possible upside of 19.4%. Raymond James has the highest price target set, predicting SLP will reach $95.00 in the next twelve months. Taglich Brothers has the lowest price target set, forecasting a price of $76.00 for Simulations Plus in the next year.
View the latest price targets for SLP.

What is the current consensus analyst rating for Simulations Plus?

Simulations Plus currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLP will outperform the market and that investors should add to their positions of Simulations Plus.
View the latest ratings for SLP.

What other companies compete with Simulations Plus?

How do I contact Simulations Plus' investor relations team?

Simulations Plus' physical mailing address is 42505 10TH STREET WEST, LANCASTER CA, 93534. The technology company's listed phone number is 661-723-7723 and its investor relations email address is [email protected] The official website for Simulations Plus is www.simulations-plus.com.